Pfizer, BioNTech Agree to Work Together on mRNA-Based Shingles Vaccine

· 20:31

BioNTech(BNTX.US)

228.605

+2.01%

07:25 AM EST, 01/05/2022 (MT Newswires) -- Pfizer (PFE) and BioNTech (BNTX) said Wednesday they have agreed to collaborate on the development of an mRNA-based vaccine for the prevention of shingles.

The companies will use an antigen technology identified by Pfizer and BioNTech's mRNA platform technology used in their COVID-19 vaccine.

BioNTech will receive $75 million in cash, $150 million in common shares, and up to $200 million in regulatory and sales milestone payments from Pfizer. Pfizer, meanwhile, will get $25 million for antigen sequences it identifies.

Clinical trials are expected to start in the second half of 2022, the companies said.

Pfizer shares were up 1.6% in recent premarket activity Wednesday, while BioNTech American depositary shares rose 1.8%.

Price: 55.33, Change: +0.8, Percent Change: +1.47